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The epidemiology of infection by Plasmodium falciparum and P. vivax was investigated among Javanese migrants
to an endemic region of Papua, Indonesia. A cohort of 243 migrants from Java was followed for malaria in a new
settlement village in the endemic Armopa area of north–eastern Papua, beginning on the day each migrant arrived
in the village. The subjects were monitored during home visits (three/week) and by the twice-monthly production
of bloodsmears that were checked for malarial parasites. At the end of 33 months, 159 (65%) of the subjects
remained under follow-up. The prevalence of parasitaemia in the village declined from 16% among those already
living there when the study began in August 1996, to 5% when the study nished in June 1999. Over this period,
596 infections by P. falciparum and 723 by P. vivax occurred in the cohort, 22 and 27 of the subjects each
experiencing at least six infections by P. falciparum and P. vivax, respectively. The incidence of malarial infection
was higher during the rst and second years post-migration (3.2 and 2.7 infections/person-year) than during the
third (1.2 infections/person-year). Although the geometric mean parasite counts for P. falciparum increased over
time (1209, 1478, and 1830 parasites/ml in the rst, second and third years, respectively), the corresponding
values for P. vivax (497, 535 and 490 parasites/ml ) showed no such trend. Only one of the nine subjects who
developed severe malaria (requiring intravenous quinine therapy) was a child, giving an odds ratio for a case of
severe malaria being in an adult of 6.1 ( P=0.08).

The published reports of numerous studies
describe the epidemiology of parasitaemia
and disease caused by Plasmodium falciparum
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and P. vivax in endemic areas. Such observations underpin hypotheses on the onset
of clinical immunity to malaria. In areas of
Africa where P. falciparum is holo-endemic,
for example, the sharp declines seen in
the prevalence and intensity of parasitaemia
and the risk of symptomatic malaria with
increasing age, beyond about 3 years, support
the hypothesis that clinical immunity is the
cumulative product of exposure to the antigenic repertoire of P. falciparum (McGregor,
1987; Newbold et al., 1997; Saul, 1999),
the slow onset of clinical immunity being
attributed to the antigenic diversity of the
parasite. In populations exposed to infection
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since birth, however, any intrinsic agedependent factors aVecting the onset of
clinical immunity are obscured. Only in previously unexposed populations of all ages
that have been abruptly and permanently
exposed to endemic malaria can the eVects
of age and cumulative exposure to infection
be separated. When Baird et al. (1991b,
1993) conducted cross-sectional studies in
such populations, they found evidence of the
age-dependent onset of clinical immunity
despite apparently equal cumulative exposure
to infection among all age-groups.
The possibility that the onset of clinical
immunity to P. falciparum is age-dependent,
and not dependent on chronic, cumulative
exposure (Baird, 1995, 1998), clearly has
implications for those attempting to develop
vaccines to diminish the burden of disease
and death caused by P. falciparum. The conventional logic underlying vaccine development is that disease can be prevented by
increasing exposure to protective antigens.
The development of a malaria vaccine, for
example, hinges largely upon strategies to
provide suYcient exposure to the surface
antigens of P. falciparum or other Plasmodium
spp. (Good et al., 1998; Plebanski and Hill,
2000). However, susceptibility to infection
and disease may be a consequence not of
insuYcient exposure to antigen but of an
inappropriate immune response driven predominantly by intrinsic factors related to
age. If so, the induction of an immune
response in infants and small children that
provides adult-like protection from disease
may require the manipulation of the intrinsic
age-related character of the immune response
to chronic exposure.
In the present study, Javanese subjects were
followed for 33 months after they migrated
to a malaria-endemic region of Indonesian
Papua. The main aim was to explore the ageand exposure-related determinants of the
onset of clinical immunity to P. falciparum
malaria. This report, the rst in a series
from this cohort, describes the methods
of recruitment, enrolment and follow-up,
along with the demographic features of the

study population and the epidemiology of
the malarial infections observed throughout
the study period.

SUBJECTS AND METHODS
Study Site
A newly constructed village, designated
Satuan Permukiman (Settlement Unit) 2 (SP2)
by the Indonesian Department of Transmigration, served as the study site. SP2 was
located at Armopa (139°32¾E, 21°6¾S) in
the Bonggo sub-district of Jayapura district
in north–eastern Papua (formerly known as
Irian Jaya), Indonesia. Housing was of uniform, wood-plank and tin-roof construction,
and laid out in a grid pattern. The village
was completed, in an area of about 4 km2
cleared of dense, lowland tropical rainforest
and located within 2 km of the Pacic Ocean,
shortly before the rst migrants arrived in
August 1996. It was fully occupied, with
1551 residents living in 450 homes, by
October 1996. The resident families had
mostly migrated from East (180 families),
Central (97) or West Java (128), although
45 families were native to Papua. The new
villagers soon established cash and subsistence
crops, primarily of soy, peanut, cassava,
melon, papaya and maize.
Perennial transmission of malaria —
primarily P. falciparum and P. vivax but
also P. malariae and P. ovale — occurs in
north–eastern Papua (Baird et al., 1990;
Jones et al., 1994). Members of the Anopheles
punctulatus group are the overwhelmingly
dominant vectors of the region (Metselaar,
1961). Most species in this group are widely
dispersed and show niche-specic habitat
preferences, their distributions often being
increased by forest clearing and the establishment of new settlements (SlooV, 1964). The
likely sources of malaria in new Papuan
villages settled entirely by malaria-naṏve
migrants are, initially, infected workers constructing the villages and, after occupation,
residents arriving from endemic areas and/or
visitors from neighbouring Papuan villages.
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There is no known occupational risk factor
for exposure to the vector mosquitoes in the
Armopa area, and such mosquitoes exhibit
no marked preference for adults (compared
with children) when blood-seeking, beyond
that attributable to the greater surface area
of adults (Burkot, 1988; Burkot et al.,
1989, 1998).

Subjects
Groups of approximately 25 families each
arrived at SP2 en masse within a day or two
of having been own, on chartered airplanes,
from Java to Papua (arriving at Sentani airport, near Jayapura). On the day of their
arrival, the newcomers were screened for
their suitability for enrolment in the present
study. Most were screened at Sentani airport, and the others were screened within
a day of their arrival at SP2. To be enrolled,
a migrant had to be aged 6–12 or "20
years, to have no history of residence in a
malarious area in the previous 5 years, to be
bloodsmear-negative for malarial parasites,
to have no splenomegaly, to be in good
general health, and give a normal result in a
test for glucose-6-phosphate-dehydrogenase
(G6PD) deciency. All of the eligible
volunteers or their guardians provided written
informed consent and all of those enrolled
were assigned study-subject identication
codes.
To ensure the treatment of the subjects
was ethical, a protocol detailing the conduct
of this study was reviewed and approved
by the institutional review boards of the
United States Navy and Indonesian Ministry
of Health. Moreover, all of the work was
performed in accordance with the relevant
regulations governing the use of such subjects — those of the Indonesian Ministry
of Health, and United States government
(code 32 of Federal Regulation, Part 219,
Protection of Human Subjects; U.S. Navy,
SECNAVINST 3900.39B).
Local authorities provided bednets (without insecticide) to all of the residents as they
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arrived. The nets were plentiful, freely available and very often used by all members of
the household, net use being encouraged by
an abundance of pest insects, rodents and
venomous snakes. Apart from the bed nets,
the housing oVered no barriers to mosquitoes,
and insect-repellent lotions were not widely
available. Each evening, most residents of
SP2 put on clothing that covered their arms
and legs, to minimize mosquito biting.

Follow-Up
The research team established a clinic in
SP2 staVed with a physician, nurse and a
team of laboratory specialists and assistants.
The clinic was the primary source of health
care for all residents of SP2. All residents
had free access to the clinic without regard
to enrolment status. Full-time paid assistants
were hired from SP2 and trained to conduct
the routine follow-up procedures and prepare bloodsmears. These ‘health workers’
visited each subject in his or her home three
times/week, to see if the subjects were in
good health. Subjects appearing ill or complaining of illness in response to a standardized
question (i.e. ‘Do you have any symptoms?’)
were referred to the study physician for
evaluation and bloodsmear examination. Any
complaint of illness prompted a bloodsmear
examination, and the subject was considered
to have symptomatic malaria if found smearpositive. Smear-positive subjects with at least
one symptom attributable to malaria were
treated promptly (see below) and began a
post-infection follow-up consisting of the
collection of a sample of venous blood on
the rst day of treatment (day 0) and day
28, and the preparation of bloodsmears on
days 0, 2, 4, 11, 14, 18, 21, 28, 35 and 42.
Routine bloodsmears prepared every 2
weeks were stained, stored and later examined
in a laboratory in Jakarta. Blood and plasma
were collected from all subjects every 2
months. Twice a year, each subject was
given a physical examination that included
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measurement of spleen size, body weight,
height and middle-upper-arm circumference
and a complete blood cell count on a QBC
counter (BD, Franklin Lakes, NJ ). This
regimen of follow-up began on the day of
arrival and enrolment in August–October
1996 and ended in July 1999, when the
study ceased.

Treatment of Malaria
As prophylaxis, all those who had just moved
to SP2 received a supervised weekly dose
of 5 mg chloroquine base/kg for a period
of 90 days, in accordance with the policy of
the Indonesian Ministries of Health and
Transmigration. Although this regimen is
ineVective in preventing parasitaemias caused
by P. falciparum or P. vivax (Baird et al.,
1995; FryauV et al., 1995), it may reduce
the risk of severe disease and death during
the 90 days of prophylaxis. On the day of
enrolment, the subjects were randomized to
either chloroquine- or meoquine-treatment
groups. Treatment of uncomplicated, slideconrmed P. falciparum malaria during the
33 months of follow-up was consistent according to this assignment for each subject:
directly observed chloroquine (Resochin ;
P.T. Bayer Indonesia, Jakarta), as doses of
10, 10 and 5 mg base/kg at 24-h intervals,
or meoquine (Lariam ; HoVman–La Roche,
Basel), as a single dose of 15 mg base/kg.
This approach addressed the hypothesis that
a curative drug (meoquine) would inhibit
or delay the onset of acquired immunity
more than a primarily suppressive drug
(chloroquine).
The occurrence of a recurrent P. falciparum
parasitaemia within 28 days of the rst
treatment dose (on day 0) was considered
a therapeutic failure and prompted the
supervised administration of a single dose of
sulfadoxine–pyrimethamine (Kimia Farma,
Bandung, Indonesia) equivalent to 25 mg
sulfadoxine and 1.25 mg pyrimethamine/kg,
and a second round of 42 days of posttherapeutic monitoring. Recurrence during

this period prompted therapy with generic
quinine (Kimia Farma), given at 10 mg/kg
three times daily for 7 days.
Subjects meeting the World Health
Organization’s criteria for severe P. falciparum
malaria (WHO, 2000) were treated with
intravenous quinine in a standard protocol:
generic quinine dihydrochloride (Kimia
Farma) at 20 mg salt/kg in 5% dextrose
saline as a 4-h loading dose, followed 4 h
later, with 10 mg salt/kg over another 4 h,
repeated every 8 h until the subject was
capable of taking oral medication.
Subjects diagnosed with P. vivax malaria
were not only treated with chloroquine
or meoquine according to assignment (as
above) but also received 15 mg primaquine
daily for 14 days.
Pre-treatment, all women with symptomatic P. falciparum malaria were tested
for pregnancy using a urine dipstick for
human chorionic gonadotropin; those found
positive received meoquine regardless of
their treatment assignment.
A physician evaluated each subject who
required therapy and recorded axillary temperature and all the physical complaints
reported by the subject, at presentation in
the clinic. The results of clinical trials in the
region demonstrated a 28-day cumulative risk
of chloroquine-treatment failure of approximately 80% for P. falciparum and 70% for
P. vivax (Baird et al., 1991a, 1997).
At 6-month intervals, as a crude gauge of
risk of infection among the study subjects,
homes in SP2 were visited at random and
occupants aged >5 years who were not
already enrolled in the present study were
asked if ngerprick samples of blood might
be collected from them. Smears of the
blood samples so collected allowed a crosssectional exploration of the prevalence and
density of parasitaemia among the SP2
residents.
The availability of antimalarial drugs outside of the clinic operated by the research
team was very limited. The village was
extremely isolated from market places by
distance, a poor road, and an incomplete
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bridge over a large river. In other words,
drugs through the research clinic were
nearby and free, whereas those in the market
places were far away and relatively expensive.
Unsupervised therapy was therefore unlikely
to have been a serious potential confounder
in the study cohort.

Classication of Infection
Each parasitaemia detected was classied as
a new infection or a recrudescence simply
on the basis of the length of time since the
patient had last been parasitaemic, only a
parasitaemia that occurred within 28 days of
a previous parasitaemia being considered a
recrudescence. The results of examining the
bloodsmears prepared routinely every 2 weeks
sometimes revealed a parasitaemia in a
subject who, though not on chemotherapy,
had not complained of any symptoms and
was afebrile when (and remained afebrile
for "24 h after) the blood sample had been
collected. Such parasitaemias were included
in the process of assigning infection sequence
during the 33 months of follow-up. An
ordered sequence of species-specic (i.e.
P. falciparum or P. vivax) new infections was
therefore determined for each subject. New
infections were further classied as febrile or
afebrile, according to the clinical records for
the day of therapy and/or blood collection.

Microscopy
The microscopical demonstration of asexual
malarial parasites in Giemsa-stained thick
smears supported all diagnoses of malaria.
The locally hired, eld-based microscopists,
all of whom had more than 7 years’ experience of checking bloodsmears, were examined
and certied competent. Only if no parasites had been detected in 200 elds at a
magnication of ×1000 was a thick smear
considered negative. Levels of parasitaemia
(asexual parasites/ml ) were estimated by
counting asexual parasites against 200 leucocytes in thick smear and assuming each
subject had 8000 leucocytes/ml.
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Entomology
Mosquito and climate surveillance began in
late August 1996 and lasted until June 1999.
During the study period, the local health
authorities conducted three spray rounds
with a residual insecticide: two (in August
1996 and March 1997) with bendiocarb
and one (in February 1998) with lambdacyhalothrin. Routine, all-night, humanlanding collections (HLC) were conducted
weekly to estimate human contact rates,
vector activity patterns and sporozoite
infection ‘rates’. Four sentinel HLC houses
were selected to derive human-landing rates
(HLR; i.e. the number of mosquitoes
captured/person-evening). The HLR were
based on the results of twice-weekly, 12-h
collections (from approximately 18.00–06.00
hours). Mosquitoes were collected, for 50 min
in each collection hour, from the exposed
legs of a trained technician, using a mouth
aspirator and ashlight. Captured mosquitoes
were placed in collection cups each hour. At
the study site, Anopheles mosquitoes were
sorted, identied by species, and stored dry,
over silica gel, until assayed for Plasmodium
infection in the laboratory in Jakarta.
Individual mosquitoes were tested, in an
ELISA (Wirtz et al., 1987), for the circumsporozoite proteins (CSP) of P. falciparum
and two P. vivax variants (Pv210 and Pv247).
Daily rainfall and maximum/minimum
ambient temperatures were recorded on site
throughout the study.

Statistical Analysis
Results were expressed as means or frequencies and analysed using unpaired
Student’s t-tests, or Mantel–Haenszel tests.
Fisher’s exact tests were used when expected
cell values were below 5.0. A P-value of
å0.05 was considered indicative of statistical
signicance. All the analyses were carried
out using version 9.0 of the SPSS (SPSS
Inc., Chicago, IL) or version 6.0 of the
Epi Info (Centers for Disease Control and
Prevention, Atlanta, GA) software packages.
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RESULTS
Screening, Enrolment, and
Withdrawal
Screening and enrolment typically occurred
as groups of 10–40 families arrived en masse.
Eleven such groups were screened between
25 August 1996 and 3 October 1996.
Screening against people likely to have a
history of exposure to malaria produced 16
exclusions among the 322 interviewed and
examined. Prior residence in a malarious area
(16) was the commonest reason among the
total of 61 exclusions. Overall, 159 adults
(aged "20 years) and 102 children (aged
6–12 years) were enrolled in the study; 131
randomized to the chloroquine- and 130 to
the meoquine-treatment group. Figure 1
illustrates the ow of subjects at screening,
enrolment and study conclusion, and Table 1
lists the demographic features of the cohort
at enrolment.
Within a few days of enrolment, 13 of
the adult subjects and ve of the children
admitted a history of residence in malarious

areas and were dropped from the study. The
remaining 146 adults and 97 children were
considered the complete cohort. Of these
243 subjects, 213 (88%) remained in the
study after the rst year, 168 (69%) after
the second year, and 159 (65%) when the
study terminated in July 1999 (Table 2).
Virtually all of the withdrawals (68 of 84)
were the result of families electing to return
to Java.

Prevalence of Parasitaemia in SP2
Although the rst of the 6-monthly,
cross-sectional examinations of bloodsmears
covered just 13% of the population (samples
collected from 163 villagers), all the subsequent prevalence samples consisted of
20%–23% of the population of SP2 (i.e.
200–268 villagers). Figure 2 illustrates the
prevalences of P. falciparum and P. vivax
infection among children (i.e. the subjects aged 6–12 years) and adults in SP2
over the period of study. Each age-specic
point represents a sample of between 18 and

FIG. 1. Flowchart showing the number of subjects available for screening, at enrolment and up to the study
conclusion. Those with glucose-6-phosphate-dehydrogenase deciency could not be excluded prior to randomization
because it took several days to test for this deciency.

50
32:18
9.1 (6–12)
22.6 (15.4–38.2)

47
31:16
9.3 (6–12)
22.8 (13–34.7)

MQ
97
63:34
9.2 (6–12)
22.7 (13–38.2)

All
72
47:25
31.9 (20–58)
51.1 (35.5–64)

CQ

74
53:21
31.7 (20–50)
52.1 (37.8–83.3)

MQ

Routine therapy*

Adults

* The subjects were randomly assigned to routine treatment of symptomatic malaria with chloroquine (CQ) or meoquine (MQ).

No. enrolled
No. of males:females
Mean age and (range) (years)
Mean weight and (range) (kg )

CQ

Routine therapy*

Children

TABLE 1. Demographic characteristics of the cohort of Javanese migrants taking up residence at SP2 in Armopa, Papua, Indonesia

146
90:46
31.8 (20–58)
51.6 (35.5–83.3)

All

243
163:80
22.8 (6–58)
40.1 (13–83.3)

All subjects
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TABLE 2. The changing size of the cohort of Javanese migrants investigated at SP2 in Armopa, Papua, Indonesia,
through the 33 months of post-migration follow-up
No. of children

No. of adults

Routine therapy*

Routine therapy*

Time

CQ

MQ

All

CQ

MQ

All

No. of subjects

Enrolment
End of Year 1
End of Year 2
End of Year 3

50
45
34
32

47
45
37
37

97
90
71
69

72
59
46
44

74
64
51
46

146
123
97
90

243
213
168
159

*The subjects were randomly assigned to routine treatment of symptomatic malaria with chloroquine (CQ) or
meoquine (MQ).

FIG. 2. The prevalences of Plasmodium falciparum parasitaemias in adults (s ) and children (d ) and of P. vivax
parasitaemias in adults (h ) and children (j ), recorded, over the course of the study, among a random sample
of residents of SP2 village who were not enrolled in the longitudinal cohort.

150 residents (median sample=48). The
prevalence of malarial infection diminished
sharply between the rst cross-sectional
survey (at month 6) and the last (at month
33), among both children and adults. There
was no signicant diVerence in the prevalences of P. falciparum and P. vivax
infection except among the adults in the rst
sample, who were much more likely to be
infected with P. vivax than P. falciparum
(27.5% v. 14.5%; P=0.043).

Number of Infections
Figure 3 illustrates the numbers of new
infections by P. falciparum or P. vivax
detected among the child and adult subjects
over the 33 months of the study. A total
of 596 infections by P. falciparum occurred
in the cohort (255 among children and
341 among adults), and 22 subjects (nine
children and 13 adults) each experienced at
least six infections by P. falciparum. A total
of 723 infections by P. vivax occurred in
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FIG. 3. The numbers of adult (h ) and child (j ) subjects in the SP2 longitudinal cohort experiencing one to
more than nine infections with Plasmodium falciparum or P. vivax.

the cohort (308 among children and 415
among adults), 27 subjects (14 children and
13 adults) each experiencing at least six
infections with this species.
Incidence of Patent Infection
Figure 4 illustrates the annual incidences
of new infections with P. falciparum and
P. vivax among the subjects enrolled in
the study. There were approximately 1.5
P. falciparum and 1.8 P. vivax infections/
subject (among both children and adults)
in the rst year. In the second year, there
were 1.2 P. falciparum and 1.4 P. vivax
infections/child, and 1.3 P. falciparum and

1.7 P. vivax infections/adult. In the third year,
the annual incidence was 0.5 P. falciparum
and 0.5 P. vivax infection/child and 0.7
P. falciparum and 0.7 P. vivax infection/
adult. Overall, the annual incidences of
malarial infection (either P. falciparum or
P. vivax) during the rst, second and third
years were 3.2, 2.7 and 1.2 infections/
subject-year, respectively.
Mean Parasite Counts
Figure 5 illustrates the geometric mean parasite counts (GMPC) for P. falciparum and
P. vivax for children and adults. Between
the rst and third years, the annual GMPC
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P. falciparum were higher in the children
than in the adults over the rst (1796 v.
935 parasites/ml; P=0.002) and third years
(2949 v. 1066 parasites/ml; P=0.03) but
not over the second year (1655 v. 1345
parasites/ml; P >0.05). The corresponding
counts for P. vivax were similar among
the children and adults during the rst year
(581 v. 448 parasites/ml; P =0.14) but signicantly higher in the children than in the
adults during both the second (763 v. 384
parasites/ml; P <0.001) and third years
(1067 v. 299 parasites/ml; P<0.001).

FIG. 4. The annual incidences of infection by
Plasmodium falciparum among the adults (s ) and children
(d ) enrolled in the SP2 cohort and by P. vivax among
the same adults (h ) and children (j ).

FIG. 5. The levels of Plasmodium falciparum parasitaemia (annual geometric mean parasite counts)
among the adults (s ) and children (d ) enrolled in the
SP2 longitudinal cohort and the corresponding values
for P. vivax among the same adults (h ) and children
(j). The vertical lines indicate 95% condence intervals.

for P. falciparum among children (1796
v. 2949 parasites/ml; P=0.20) and adults
(935 v. 1066 parasites/ml; P =0.66) showed
no signicant change. The GMPC for

Severe Malaria
During the study, 31 residents of SP2
developed severe malaria requiring intravenous-quinine management. All 22 of these
cases who were not enrolled in the study had
slide-proven P. falciparum malaria. Six of
these 22 cases were children and three (all
children) died.
Among the other nine cases of severe
malaria — eight adults and one child,
who were all enrolled on the study and all
of whom survived — one appeared smearpositive for P. vivax only and the rest
smear-positive for P. falciparum. The severe
episode of P. vivax malaria occurred with
the rst infection whereas the severe attacks
of P. falciparum malaria occurred with the
rst (two cases), third (four) or fourth
infections (two). The odds ratio for a
P. falciparum infection developing into severe
malaria in an adult subject, compared with
that in a child, was 6.1 ( P=0.08).

Entomology
Members of the Anopheles punctulatus group
were collected year-round over the course
of the study. Based on both morphological
and molecular analysis, Anopheles punctulatus
Doentz, Anopheles koliensis Owen, Anopheles
farauti Laveran and Anopheles farauti No. 4
(a sibling species) were identied in collections
from inside and outside the sentinel homes.

MALARIA IN NON-IMMUNE MIGRANTS

For the purpose of data analysis and the
ELISA, both sibling species of An. farauti
were grouped together (as An. farauti s.l.).
The predominant species encountered was
An. punctulatus, followed by An. farauti s.l.
Vector biting rates typically increased during
and immediately after the wet months of
the year (November–March) and decreased
to far lower levels during the drier months
(May–October; see Figure 6). In early 1998,
indoor and outdoor anopheline biting densities
declined markedly, and remained relatively
low until the end of the study.
Between April and May 1997, a 97%
reduction in the HLR was recorded. This
was attributed to the second round of indoor
spraying with bendiocarb, in late March
1997. The total number of anophelines
captured in 1998–1999 was >84% lower
than the number caught in 1996–1997. A
sustained, general suppression in mosquito
population densities continued into 1998
and 1999, with only small adult-activity peaks
seen during the wet months of September–
October 1998 and February–April 1999. The
ELISA-based estimates of the combined
indoor/outdoor sporozoite ‘rates’ remained
around 0.2% throughout the study period.

FIG. 6.
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DISCUSSION
The incidence of infection by P. falciparum
in the study cohort was approximately 1.5
infections/person-year during the rst 2
years, and just 0.6 infection/person-year in
the third year. Most subjects experienced
only three or four infections with this parasite during the study. The incidence of
P. falciparum infection in the Armopa region
was also relatively low (Baird et al., 2001)
but that observed in the Arso region, where
the original cross-sectional studies of Javanese
transmigrants were conducted (Baird et al.,
1991b, 1993), was much higher. The results
of longitudinal studies of malaria attack in
the Arso region typically indicated an annual
incidence of two to four P. falciparum
infections/person ( Jones et al., 1994; Ohrt
et al., 1997; Taylor et al., 1999). Infection
incidence is a critical issue to those exploring
the onset of clinical immunity to P. falciparum,
because the attack rates in Arso and Armopa
and the results of repeated challenge of neurosyphilis patients with P. falciparum (Ciuca
et al., 1934) indicate that such immunity
may require at least four infections within
12–24 months (Baird et al., 2003). Unlike

The monthly mean levels of anopheline-mosquito biting in SP2 over the course of the longitudinal study.
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those who live in the Arso region, relatively
few residents of SP2 would have experienced
such exposure during the period of the present study. This diVerence may explain why,
after more than 2 years of exposure, the
prevalence of P. falciparum parasitaemia
among the children investigated in SP2 was
similar to that in the adults (Fig. 2) whereas
in Arso the adults were much less likely
to be parasitaemic than the children (Baird
et al., 1991b, 1993).
Several key factors probably explain the
relatively low risk of infection in SP2 compared with that in the Arso region. There is
clearly an ethical responsibility to execute a
programme of close surveillance and prompt
treatment among a cohort of essentially nonimmune subjects exposed to a potentially
life-threatening infection. Application of such
a strategy in SP2 almost certainly curtailed
the pool of infectious people and thereby
articially reduced the incidence of infection.
Indeed, over the course of the study, sharp
drops in the prevalence of parasitaemia in
the village and in the incidence of infection
among the study subjects were observed.
Also, the numbers of biting anophelines
sharply declined following a routine, indoor
application of a residual insecticide throughout the village. Finally, an important distinction between the habitat of the Arso
study sites and those in Armopa is the
amount of cleared versus forested land; a new
palm-oil plantation dominated the habitat
surrounding the Arso sites whereas virgin
forest surrounded the Armopa study sites.
This may be the most important factor
because only at the one study site in the
Arso region that was surrounded by forest
rather than palm-oil plantation was the
annual incidence of P. falciparum infection
found to be as low (1.1 infections/person;
FryauV et al., 1995) as those recorded in the
Armopa region, either in SP2 (1.1/person;
present study) or elsewhere (0.9/person;
Baird et al., 2001).
The present results indicate that, in
SP2 over the study period, the risk of
patent infection was similar for the children

and adults; the incidence of infection by
P. falciparum in the SP2 cohort over 33
months was 1.11 infections/child-year and
1.10/adult-year. A similar analysis restricted
to rst infections also showed virtually
identical risk for the children and adults
(Barcus et al., 2003). Baird et al. (1991b)
thought that the risk of infection (i.e. sporozoite inoculation) in Arso was probably
similar for children and adults because the
main local vectors tend to breed near to
houses and to blood-feed predominantly
around homes at night (SlooV, 1964; Burkot,
1988; Burkot et al., 1989). That the prevalence of parasitaemia during early exposure
to risk appeared to be unaVected by subject
age supported that view (Baird et al., 1993).
The diVerences in susceptibility to infection
and disease observed between children and
adult migrants have therefore been attributed
to age-related diVerences in immune response
rather than to diVerences in cumulative
experience with infection (Baird et al., 1991b,
1993; Baird, 1995, 1998). The results of
the research in SP2 conrm that, in rural,
north–eastern Indonesian Papua, the risk of
exposure to infection in children is practically
the same as that in adults.
Severe disease rarely occurred in the
SP2 cohort. Only nine of the study subjects required intravenous quinine over the
33-month study period. This contrasts with
the situation in villages lacking the active
surveillance and prompt therapy aVorded to
the study subjects. During the rst 2 years
at Arso PIR IV, for example, the monthly
incidence of severe malaria requiring evacuation to hospital, among the adult Javanese
migrants, was typically 0.5 case/person-year
and peaked at 1.4 cases/person-year during
the rst 6 months (Baird et al., 1998). In
SP2, the eight cases of P. falciparum malaria
who required intravenous quinine (also predominantly adult subjects) represented a
corresponding incidence of only 0.01 case/
person-year. In other words, subjects in the
cohort at SP2 were at least 50 times less
likely to develop severe disease than similar

MALARIA IN NON-IMMUNE MIGRANTS

migrants in the Arso region. This is almost
certainly the product of prompt diagnosis
and treatment in SP2, and the consequent
reductions in the prevalence of parasitaemia
and therefore risk of severe disease. The SP2
cohort does not represent patterns of risk of
severe malaria among most non-immune
migrants to Indonesian Papua, who live in
villages where the facilities for surveillance,
diagnosis and treatment are far more limited.
In summary, the incidence of P. falciparum
infection, or P. vivax infection, among
both children and adults during their rst
33 months at SP2 was about 1.1 infections/
person-year. That this rate was relatively low
compared with rates measured earlier, in
the Arso region, was probably the result of
prompt diagnosis and treatment, along with
diminished vector abundance. The onset of
clinical immunity, observed in most residents
in the Arso study sites, was therefore anticipated to be limited to the minority of the
cohort experiencing at least four infections
within 1 or 2 years.
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